论文部分内容阅读
尽管α-干扰素(IFN-α)已用于治疗慢性丙型肝炎(CHC),但很少病人有长期效应。本文作者研究了与IFN疗效有关的几个因素:丙型肝炎病毒(HCV)基因型、RNA水平、组织学特征、IFN剂量、生物化学标记及年龄等。 选择抗-HCV阳性(ELISA-2)但无肝硬变的活动性CHC病人60例,其中35例(1组),用人淋巴母细胞IFN治疗,5MU,每周3次,疗程24周(总量360MU);另25例(2组)先用5MU,每周3次,治疗12周,然后用2.5MU,每周3次,疗程24周(总剂量
Although alpha-interferon (IFN-alpha) has been used to treat chronic hepatitis C (CHC), few patients have long-term effects. The authors investigated several factors related to the efficacy of IFN: hepatitis C virus (HCV) genotypes, RNA levels, histological features, IFN doses, biochemical markers, and age. Sixty patients with active CHC who were positive for anti-HCV (ELISA-2) but no cirrhosis were enrolled, of whom 35 (n = 1) received IFN treatment with human lymphoblastoid cells at 5 MU for 3 weeks per week for 24 weeks Amount of 360MU); the other 25 patients (2 groups) were treated with 5MU 3 times a week for 12 weeks and then 2.5MU 3 times a week for 24 weeks (total dose